MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 02-09-2023
Cardiovascular Systems Balance Sheet 2011-2026 | CSII
Annual Balance Sheet Cardiovascular Systems
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-64.6 M | -68.9 M | - | -53.3 M | -95.2 M | -86.8 M | -60.6 M | -83.8 M | -124 M | -55.3 M | -18 M | -9.02 M |
Long Term Debt |
1.33 M | 1.72 M | - | - | - | - | - | - | - | 7.47 M | 12.8 M | 8.33 M |
Long Term Debt Current |
526 K | 487 K | - | - | - | - | - | - | 2.4 M | 5.1 M | 4.68 M | - |
Total Non Current Liabilities |
- | - | - | 28.3 M | 31.4 M | 34.6 M | 6.01 M | 2 M | 117 K | 7.65 M | 13.1 M | 9.94 M |
Total Current Liabilities |
40 M | 54.6 M | 44.5 M | 42.3 M | 37.5 M | 41 M | 35.5 M | 29.9 M | 29.7 M | 22.4 M | 17.9 M | - |
Total Liabilities |
73.2 M | 81.6 M | 70.7 M | 70.6 M | 68.9 M | 75.6 M | 41.5 M | 31.9 M | 29.8 M | 30.1 M | 30.9 M | 25.1 M |
Deferred Revenue |
2.11 M | 2.4 M | 1.87 M | 1.76 M | 1.24 M | - | - | - | 59 K | 156 K | - | - |
Retained Earnings |
-424 M | -381 M | -363 M | -330 M | -328 M | -329 M | -327 M | -271 M | -239 M | -203 M | -179 M | -162 M |
Total Assets |
323 M | 353 M | 340 M | 219 M | 203 M | 194 M | 142 M | 171 M | 182 M | 96.9 M | 63.1 M | 46.8 M |
Cash and Cash Equivalents |
66.4 M | 71.1 M | 185 M | 74.2 M | 116 M | 108 M | 60.6 M | 83.8 M | 127 M | 67.9 M | 35.5 M | 21.2 M |
Book Value |
249 M | 271 M | 269 M | 148 M | 134 M | 118 M | 101 M | 139 M | 152 M | 66.8 M | 32.2 M | 21.6 M |
Total Shareholders Equity |
249 M | 271 M | 269 M | 148 M | 134 M | 118 M | 101 M | 139 M | 152 M | 66.8 M | 32.2 M | 21.6 M |
All numbers in USD currency
Quarterly Balance Sheet Cardiovascular Systems
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
1.11 M | 1.22 M | 1.33 M | 1.43 M | 1.52 M | 1.64 M | 1.72 M | 1.72 M | 1.94 M | 2.05 M | 15 K | 57 K | 175 K | 306 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.74 M | 7.47 M | 7.47 M | 10.4 M | 11.6 M | 12.8 M | 12.8 M | 15.4 M | 8.44 M | 8.33 M | 8.33 M |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 117 K | 112 K | 123 K | 5.9 M | 7.65 M | 7.65 M | 10.6 M | 11.8 M | 13.1 M | 13.1 M | 15.8 M | 9.86 M | 9.94 M | 9.94 M |
Total Liabilities |
72.1 M | 69.9 M | 73.2 M | 70.5 M | 66.9 M | 69.1 M | 81.6 M | 81.6 M | 75.1 M | 73.3 M | 70.7 M | 76.9 M | 80.9 M | 75 M | 70.6 M | 70.6 M | 68.6 M | 66.3 M | 68.9 M | 68.9 M | 66.1 M | 70.3 M | 75.6 M | 75.6 M | 46.6 M | 35.4 M | 41.5 M | 41.5 M | 30 M | 31.8 M | 31.9 M | 31.9 M | 32.5 M | 33.9 M | 29.8 M | 29.8 M | 24.9 M | 29.8 M | 30.1 M | 30.1 M | 27.5 M | 31.1 M | 30.9 M | 30.9 M | 30.1 M | 25 M | 25.1 M | 25.1 M |
Deferred Revenue |
525 K | 694 K | 2.11 M | 2.81 M | 2.72 M | 2.49 M | 2.4 M | 2.4 M | 2.08 M | 2.09 M | 1.87 M | 1.76 M | 1.66 M | 1.71 M | 1.76 M | 1.76 M | 1.52 M | 1.25 M | 1.24 M | 1.24 M | 1.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-443 M | -436 M | -424 M | -414 M | -404 M | -395 M | -381 M | -381 M | -369 M | -369 M | -363 M | -348 M | -345 M | -341 M | -330 M | -330 M | -331 M | -331 M | -328 M | -331 M | -332 M | -331 M | -329 M | -329 M | -328 M | -329 M | -327 M | -327 M | -300 M | -285 M | -271 M | -271 M | -252 M | -247 M | -239 M | -239 M | -219 M | -211 M | -203 M | -203 M | -190 M | -184 M | -179 M | -179 M | -170 M | -166 M | -162 M | -162 M |
Total Assets |
312 M | 312 M | 323 M | 324 M | 326 M | 332 M | 353 M | 353 M | 349 M | 342 M | 340 M | 220 M | 224 M | 217 M | 219 M | 219 M | 207 M | 200 M | 203 M | 203 M | 190 M | 190 M | 194 M | 194 M | 159 M | 138 M | 142 M | 142 M | 151 M | 162 M | 171 M | 171 M | 181 M | 182 M | 182 M | 182 M | 181 M | 95.1 M | 96.9 M | 96.9 M | 56.6 M | 60.1 M | 63.1 M | 63.1 M | 52 M | 48.3 M | 46.8 M | 46.8 M |
Cash and Cash Equivalents |
59.8 M | 62.8 M | 66.4 M | 67 M | 65.9 M | 66.9 M | 71.1 M | 71.1 M | 73.8 M | 92.7 M | 73.8 M | 69.6 M | 65.5 M | 58.9 M | 65.5 M | 58.9 M | 119 M | 113 M | 119 M | 113 M | 107 M | 105 M | 107 M | 105 M | 79.3 M | 58.2 M | 79.3 M | 58.2 M | 62.2 M | 76.7 M | 65.3 M | 76.7 M | 101 M | 116 M | 101 M | 116 M | 147 M | 63.2 M | 147 M | 63.2 M | 29.2 M | 32.2 M | 29.2 M | 32.2 M | 24.6 M | 22.7 M | 24.6 M | 22.7 M |
Book Value |
239 M | 242 M | 249 M | 253 M | 260 M | 263 M | 271 M | 271 M | 274 M | 268 M | 269 M | 143 M | 143 M | 142 M | 148 M | 148 M | 139 M | 134 M | 134 M | 134 M | 124 M | 120 M | 118 M | 118 M | 112 M | 103 M | 101 M | 101 M | 121 M | 131 M | 139 M | 139 M | 148 M | 148 M | 152 M | 152 M | 156 M | 65.3 M | 66.8 M | 66.8 M | 29.2 M | 29 M | 32.2 M | 32.2 M | 21.9 M | 23.3 M | 21.6 M | 21.6 M |
Total Shareholders Equity |
239 M | 242 M | 249 M | 253 M | 260 M | 263 M | 271 M | 263 M | 274 M | 268 M | 274 M | 143 M | 143 M | 143 M | 143 M | 142 M | 139 M | 139 M | 139 M | 134 M | 124 M | 120 M | 124 M | 120 M | 112 M | 103 M | 101 M | 101 M | 121 M | 131 M | 139 M | 139 M | 148 M | 148 M | 152 M | 152 M | 156 M | 65.3 M | 66.8 M | 66.8 M | 29.2 M | 29 M | 32.2 M | 32.2 M | 21.9 M | 23.3 M | 21.6 M | 21.6 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Cardiovascular Systems, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Medical devices
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
LivaNova PLC
LIVN
|
$ 62.73 | -0.81 % | $ 3.42 B |  Britain |
 |
GenMark Diagnostics, Inc.
GNMK
|
- | - | $ 1.77 B |  USA |
 |
Axonics Modulation Technologies
AXNX
|
- | - | $ 3.31 B | USA |
 |
Lianluo Smart Limited
LLIT
|
- | 24.59 % | $ 44.8 M |  China |
 |
Aziyo Biologics
AZYO
|
- | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
- | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
- | -5.86 % | $ 30.6 M | USA |
 |
BioSig Technologies
BSGM
|
- | 37.08 % | $ 85.7 M | USA |
 |
Medtronic PLC
MDT
|
$ 86.97 | -0.28 % | $ 112 B | USA |
 |
Conformis
CFMS
|
- | - | $ 16.4 M | USA |
 |
IRIDEX Corporation
IRIX
|
$ 1.37 | 1.48 % | $ 22.1 M | USA |
 |
Apollo Endosurgery
APEN
|
- | - | $ 475 M | USA |
 |
LENSAR
LNSR
|
$ 5.59 | -7.91 % | $ 64.4 M | USA |
 |
Avinger
AVGR
|
- | -20.74 % | $ 369 K | USA |
 |
CryoLife, Inc.
CRY
|
- | -4.14 % | $ 702 M | USA |
 |
CHF Solutions, Inc.
CHFS
|
- | 1.15 % | $ 34.5 M | USA |
 |
AxoGen
AXGN
|
$ 32.65 | 2.83 % | $ 1.5 B | USA |
 |
CONMED Corporation
CNMD
|
$ 36.74 | 0.3 % | $ 1.14 B | USA |
 |
Soliton, Inc.
SOLY
|
- | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
- | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
- | 0.03 % | $ 1.58 B |  Israel |
 |
Orthofix Medical
OFIX
|
$ 11.8 | -0.59 % | $ 467 M |  Curacao |
 |
Electromed
ELMD
|
$ 24.81 | 1.29 % | $ 210 M | USA |
 |
Misonix, Inc.
MSON
|
- | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
- | - | $ 111 M |  Canada |
 |
Intersect ENT, Inc.
XENT
|
- | - | $ 955 M | USA |
 |
Cytosorbents Corporation
CTSO
|
$ 0.72 | 7.39 % | $ 39.2 M | USA |
 |
Aethlon Medical
AEMD
|
$ 2.16 | -6.09 % | $ 3.37 M | USA |
 |
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | USA |
 |
Penumbra
PEN
|
$ 334.7 | -0.27 % | $ 13 B | USA |
 |
AdaptHealth Corp.
AHCO
|
$ 11.59 | 11.76 % | $ 1.57 B | USA |
 |
Myomo
MYO
|
$ 0.7 | -1.85 % | $ 29.3 M | USA |
 |
Insulet Corporation
PODD
|
$ 226.67 | -0.18 % | $ 15.9 B | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 2.42 | -0.82 % | $ 142 M | Israel |
 |
Invacare Corporation
IVC
|
- | - | $ 24.7 M | USA |
 |
EDAP TMS S.A.
EDAP
|
$ 3.88 | 4.02 % | $ 145 M |  France |
 |
Profound Medical Corp.
PROF
|
$ 5.19 | -3.89 % | $ 180 M | Canada |
 |
OrthoPediatrics Corp.
KIDS
|
$ 15.96 | -3.1 % | $ 374 M | USA |
 |
Outset Medical
OM
|
$ 3.59 | -0.69 % | $ 54.6 K | USA |
 |
Quanterix Corporation
QTRX
|
$ 3.86 | -2.03 % | $ 165 M | USA |
 |
Inspire Medical Systems
INSP
|
$ 51.94 | -0.52 % | $ 1.53 B | USA |
 |
Pulmonx Corporation
LUNG
|
$ 1.33 | -4.68 % | $ 54.1 M | USA |
 |
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | USA |
 |
Dynatronics Corporation
DYNT
|
- | 14.99 % | $ 929 K | USA |
 |
Sintx Technologies
SINT
|
$ 2.59 | 1.57 % | $ 7.18 M | USA |
 |
InspireMD
NSPR
|
$ 1.79 | 2.59 % | $ 115 M | Israel |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
NuVasive
NUVA
|
- | - | $ 2.07 B | USA |